G. Bruce Mann

home / authors / g-bruce-mann

Articles

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

Julie A. Margenthaler, MD;Karuna Mittal;Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Brian Czerniecki;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Steven C. Shivers;Troy Bremer
April 26th 2023
39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

Rachel Rabinovitch, MD;Frank A. Vicini, MD;Chirag Shah, MD;Julie A. Margenthaler, MD;Brian Czerniecki;Pat W. Whitworth;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer
April 26th 2023
40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Julie A. Margenthaler, MD;Brian Czerniecki;David J. Dabbs;Sheila Weinmann;Michael Leo;G. Bruce Mann;Fredrik Wärnberg;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer
April 26th 2023
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

Steven C. Shivers;Pat W. Whitworth;Rachel Rabinovitch, MD;Frank Vicini, MD;Chirag Shah, MD;Fredrik Wärnberg;G. Bruce Mann;Karuna Mittal;Troy Bremer
May 6th 2022
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

Pat W. Whitworth;Rachel Rabinovitch, MD;Frank A. Vicini, MD;Chirag Shah, MD;Fredrik Wärnberg;G. Bruce Mann;Steven C. Shivers;Karuna Mittal;Troy Bremer
May 6th 2022

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Published: November 7th 2024 | Updated: November 21st 2024
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Treatment Considerations for Disease Progression
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Considerations for Disease Progression
Treatment Paradigm for Metastatic Pancreatic Cancer
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Paradigm for Metastatic Pancreatic Cancer